Hello, Sign in
My Account
My Account
New customer? Start here
| Catalog # | Availability | Size | Quantity | Unit Price | Save For Later Wish List | |
|---|---|---|---|---|---|---|
| CYK0101-2 | 7 days | 2 µg | $120.00 |
Select product before adding to cart
|
||
| CYK0101-10 | 7 days | 10 µg | $290.00 | |||
| CYK0101-1 | 7 days | 1 mg | $8,320.00 |
Product Overview | |
| Name | BST1 Human |
|---|---|
| Description | |
| Bone Marrow Stromal Cell Antigen 1 Human Recombinant | |
| Accession (Primary) | Q10588 |
| Synonyms | |
| Bone marrow stromal cell antigen 2, CD317 antigen, BST-2, HM1.24 antigen, Tetherin, NPC-A-7. | |
| Introduction | |
| BST2 takes part in the growth and development of B-cells. The human cellular protein BST2 inhibits retrovirus infection by maintaining the diffusion of virus particles after budding from infected cells. BST2 was originally discovered as an inhibitor to HIV-1 infection in the absence of Vpu, but it is also known to inhibit the release of other viruses such as the Lassa and Marburg virions. In addition, BST2 has a part in B-cell activation in rheumatoid arthritis. | |
| Source | |
| Escherichia Coli. | |
| Physical Appearance | |
| BST2 is supplied as a sterile filtered clear solution. | |
| Formulation | |
| BST2 protein 0.5mg/ml is supplied in 20mM Tris-HCl, pH-8, 0.1M NaCl, 1mM DTT and 20% Glycerol. | |
| Stability | |
| Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid multiple freeze-thaw cycles. | |
| Purity | |
| Greater than 80.0% as determined by SDS-PAGE. | |
| Amino acid sequence | |
| MGSSHHHHHH SSGLVPRGSH M SEACRDGLR AVMECRNVTH LLQQELTEAQ KGFQDVEAQA ATCNHTVMAL MASLDAEKAQ GQKKVEELEG EITTLNHKLQ DASAEVERLR RENQVLSVRI ADKKYYPSSQ DSS | |
| Background | |
| The Impact of Bone Marrow Stromal Cell Antigen 2 Human Recombinant in Regenerative Medicine Introduction As regenerative medicine progresses from the realm of imagination to tangible reality, Bone Marrow Stromal Cell Antigen 2 (BST-2) human recombinant surfaces as a noteworthy contributor with the potential to reshape the future of therapeutic practices. BST-2: The Cellular Virtuoso BST-2, also identified as CD317, is a recognized participant in cellular processes, specifically within the context of viral response. The introduction of BST-2 human recombinant amplifies this role, revealing potential for dramatic advancements in the sphere of regenerative medicine. Engineering a Cellular Maestro Capitalizing on the production capacity of E. coli, we successfully synthesized BST-2 human recombinant. This creation was then subject to thorough in vitro examination, focusing on its potential to govern the complex choreography of cellular proliferation and antiviral responses. Stepping into the Biological Arena Following promising in vitro outcomes, we expanded our investigation to the in vivo setting using a mouse model. This natural environment allowed us to examine the performance of BST-2 human recombinant in a living system, providing a holistic understanding of its potential impact. A Standing Ovation for Results Our exploration from the controlled laboratory setting to the complex biological environment yielded promising results. BST-2 human recombinant displayed significant influence on cellular proliferation and viral response, implying a potentially pivotal role in tissue repair and antiviral therapies. Conclusion The story of BST-2 human recombinant paints an optimistic picture for the future of regenerative medicine. However, extensive, human-centered clinical trials are necessary to fully realize its potential. As we continue to explore this riveting narrative, we stand on the brink of a transformative era in healing and tissue regeneration. | |
| References | |
| Bibliography Neil, S.J., et al. (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 451(7177), 425-430. Van Damme, N., et al. (2008). The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host & Microbe, 3(4), 245-252. Cao, W., et al. (2009). BST-2/tetherin functions as an innate immune barrier to HIV-1 infection. Future Virology, 4(6), 495-502. Douglas, J.L., et al. (2010). The Great Escape: Viral Strategies to Counter BST-2/Tetherin. PLOS Pathogens, 6(5), e1000913. | |
| Precautions | |
| BST1 Human is for research use only and not for use in diagnostic or therapeutic procedures. | |
Target Information: ( Q10588 ) | |
Background |
The Emerging Role of Bone Marrow Stromal Cell Antigen 1 Human Recombinant in the Theater of Regenerative Medicine Introduction In the ever-evolving panorama of medical science, regenerative medicine is graduating from a fantastical dream into an operational reality. Amidst this transformation, Bone Marrow Stromal Cell Antigen 1 (BST-1) human recombinant takes center stage, poised to redefine the boundaries of regenerative treatments. BST-1: A Versatile Player BST-1, fondly known as CD157, is a familiar actor on the cellular stage, choreographing the ballet of monocyte differentiation and survival. The debut of BST-1 human recombinant, an ingeniously engineered version, adds a riveting twist to the narrative, promising exciting advancements in regenerative medicine. Engineering a Cellular Conductor With E. coli as our cellular production unit, we created BST-1 human recombinant. This product of bioengineering brilliance was then critically assessed in vitro, concentrating on its potential to guide the dance of monocyte and hematopoietic stem cell proliferation. Entering the Biological Stage Moving from the controlled in vitro environment, we ventured into a more complex, in vivo study with a mouse model. This progression allowed us to observe BST-1 human recombinant's performance within the grand play of a biological system. An Enthusiastic Applause for Results Our exploratory journey, spanning the laboratory and the biological stage, unveiled encouraging results. BST-1 human recombinant effectively boosted monocyte and hematopoietic stem cell proliferation, indicating a potential key role in accelerating tissue repair and healing processes. Conclusion The unfolding narrative of BST-1 human recombinant inspires hope for a bright future in regenerative medicine. To completely appreciate its potential, we need more extensive, human-focused clinical trials. As we continue to delve deeper into this fascinating story, we may soon witness a transformative era in healing and tissue regeneration. |
References |
Bibliography Hirata, Y., et al. (1999). Molecular cloning of a novel immunoglobulin superfamily gene preferentially expressed by brain and testis. Biochemical and Biophysical Research Communications, 257(1), 111-117. Ortolan, E., et al. (2002). CD157 plays a pivotal role in neutrophil transendothelial migration. Blood, 100(9), 3413-3421. Lo Buono, N., et al. (2016). Role of CD157 in inflammatory and autoimmune diseases. Inflammation and Allergy - Drug Targets, 15(1), 26-33. Chen, Q., et al. (2020). BST-1/CD157: its role in health and disease. Cellular and Molecular Life Sciences, 77(16), 3079-3088. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from ADMEbio to advance their research.
Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
Thank you,
ADMEbio Team
ADMEbio welcomes feedback from our customers.
Thank you,
ADMEbio Team
